One of the most deadly genetic disorders affecting humans today is Myotonic Dystrophy Type I(DM1); in fact, DM1 is one of the leading causes of adult Muscular Dystrophy. The good news is that there have been scientific advances in recent years and 5AM Ventures, a firm lead by Scott Rocklage that helps develop life science companies in their early phases, is helping raise the money to find an effective treatment.
DM1 is passed down from generation to generation, and finding a drug to combat it has long been a goal of the medical community. Working with 5AM Ventures, a company called Expansion Therapeutics is leading the effort by using the research done by Dr. Matthew Disney, an expert in the field of genetic diseases. Dr. Disney has been researching the problem of fighting RNA-related genetic diseases for roughly 12 years and feels that a treatment is just around the corner.
Scott Rocklage and 5AM Ventures
To say that Scott Rocklage is highly educated and extremely accomplished is a bit of an understatement. He earned a Bachelor’s degree in chemistry from the University of California at Berkeley and a Doctorate in chemistry from the Massachusetts Institute of Technology. While at MIT, he worked at the laboratory of famed scientist Dr. Richard Schrock, who was awarded the Nobel prize in 2005.
During his career, Rocklage has helped numerous medications gain FDA approval and has published many articles in peer-reviewed journals. A businessman and entrepreneur as well as a scientist, Scott Rocklage formed 5AM Ventures in 2003.
To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.